Roche Diagnostics Operations, Inc.

Universiteit Maastricht

Academisch Ziekenhuis Maastricht

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Andre Ziegler

Ursula-Henrike Wienhues-Thelen

Johann Karl

Dirk Block

Christian Zaugg

Thomas Dieterle

Edelgard Anna Kaiser

Hans-Peter Brunner

Roberto Latini

Serge Masson

Vinzent Rolny

Peter Kastner

James Januzzi

Julian Braz

Herbert Andres

Ulrich Schotten

Stefan Palme

Viveka Frykmann-Kull

Emma Svennberg

Leif Friberg

Hanspeter Brunner

Simona Barlera

Markus Thomas

Marten Rosenquist

David Conen

Manuel Dietrich

Mathias Emil Egermark

Uli Schotten

Disclosed is a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of ESM-1 in a sample from the subject, and comparing the amount of ESM-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure is disclosed.

Circulating ESM-1 (endocan) in the assessment of atrial fibrillation and/or stroke

The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.

Circulating Angiopoietin-2 (Ang-2) and insulin-like growth factor-binding protein 7 (IGFBP7) for the prediction of stroke

A method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on measuring the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject is described. Also described is a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on measuring the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Also described are devices adapted to carry out the method of the present disclosure.

Circulating Angiopoietin-2 (Ang-2) for the prediction of recurrence of atrial fibrillation

The present disclosure is directed to a method of identifying a patient having heart failure as likely to respond to a therapy with a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein the patient has heart failure and undergoes a therapy with a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.

Marker for statin treatment stratification in heart failure

Presented is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also described are kits and devices adapted to carry out the method.

IGFBP7 for diagnosing diastolic dysfunction

Disclosed herein is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Also disclosed is a method of monitoring diastolic function in a patient suffering from heart failure, and kits and devices for performing the method.

The present invention relates to a method of diagnosing whether a subject with no known history of atrial fibrillation is suffering from atrial fibrillation, or not, said method comprising the steps of a) determining the amount of a BNP-type peptide in a sample of said subject; b) comparing the amount the BNP-type peptide to a reference, and c) assessing intermittent ECG recordings obtained from said subject over a period of at least one week by using a handheld ECG device.

Algorithm of NTproBNP and hand held ECG to detect arrhythmia in an elderly population

The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.

Growing community of inventors

Laeufelfingen, Switzerland

Andre Ziegler